KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Change in Cash: 2010-2025

Historic Change in Cash for Novavax (NVAX) over the last 15 years, with Sep 2025 value amounting to $14.4 million.

  • Novavax's Change in Cash rose 113.44% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$305.2 million, marking a year-over-year decrease of 292.45%. This contributed to the annual value of -$38.5 million for FY2024, which is 94.97% up from last year.
  • Novavax's Change in Cash amounted to $14.4 million in Q3 2025, which was up 251.35% from -$9.5 million recorded in Q2 2025.
  • Over the past 5 years, Novavax's Change in Cash peaked at $1.4 billion during Q1 2021, and registered a low of -$711.9 million during Q1 2023.
  • Over the past 3 years, Novavax's median Change in Cash value was -$82.6 million (recorded in 2023), while the average stood at -$96.9 million.
  • As far as peak fluctuations go, Novavax's Change in Cash spiked by 1,214.45% in 2021, and later tumbled by 1,374.87% in 2023.
  • Over the past 5 years, Novavax's Change in Cash (Quarterly) stood at -$418.6 million in 2021, then spiked by 113.34% to $55.8 million in 2022, then plummeted by 247.88% to -$82.6 million in 2023, then spiked by 47.55% to -$43.3 million in 2024, then soared by 113.44% to $14.4 million in 2025.
  • Its last three reported values are $14.4 million in Q3 2025, -$9.5 million for Q2 2025, and -$266.8 million during Q1 2025.